The impact of ventricular remodeling on quality-of-life outcomes after Transcatheter aortic valve replacement.

Hypertrophy Left ventricular hypertrophy Quality of life Remodeling Transcatheter aortic valve replacement

Journal

Journal of cardiology
ISSN: 1876-4738
Titre abrégé: J Cardiol
Pays: Netherlands
ID NLM: 8804703

Informations de publication

Date de publication:
19 Oct 2024
Historique:
received: 27 04 2024
revised: 01 10 2024
accepted: 07 10 2024
medline: 22 10 2024
pubmed: 22 10 2024
entrez: 21 10 2024
Statut: aheadofprint

Résumé

Among patients with aortic stenosis, ventricular remodeling by hypertrophy can limit the augmentation of flow with exertion, even after valve intervention. However, the effect of hypertrophy on quality of life (QoL) improvement has not been studied. We aimed to determine the effect of ventricular hypertrophy on QoL outcomes after transcatheter aortic valve replacement (TAVR). All patients undergoing TAVR from 2011 to 2021 at our institution were included. Groups were divided into none/mild ventricular hypertrophy (non-remodeled, NR) and moderate/severe left ventricular hypertrophy (VH) according to guideline-recommended cut-offs for left ventricular (LV) wall thickness. The Kansas City Cardiomyopathy Questionnaire (KCCQ) was utilized to assess QoL; primary outcome was KCCQ change <5 from baseline to 30 days and 1 year. We analyzed 679 patients (NR: N = 389, VH: N = 290). Groups differed by septal thickness (1.12 cm vs. 1.44 cm, p < 0.001), posterior wall thickness (1.08 cm vs. 1.33 cm, p < 0.001), and LV internal diastolic diameter (4.34 cm vs. 4.19 cm, p = 0.006). The primary outcome was similar between NR and VH at 30 days (31.6 % vs. 28.6 %, p = 0.449) and 1 year (27.7 % vs. 21.5 %, p = 0.217). NR and VH experienced similar proportions of worsening, no change, or small, moderate, and large improvements in KCCQ score. Both groups experienced similar domain score changes and New York Heart Association class improvement. A subgroup analysis of VH patients did not reveal interaction with cavity size or stroke volume. Patients with significant ventricular remodeling by hypertrophy and aortic stenosis have similar QoL changes after intervention compared to patients without significant remodeling.

Sections du résumé

BACKGROUND BACKGROUND
Among patients with aortic stenosis, ventricular remodeling by hypertrophy can limit the augmentation of flow with exertion, even after valve intervention. However, the effect of hypertrophy on quality of life (QoL) improvement has not been studied. We aimed to determine the effect of ventricular hypertrophy on QoL outcomes after transcatheter aortic valve replacement (TAVR).
METHODS METHODS
All patients undergoing TAVR from 2011 to 2021 at our institution were included. Groups were divided into none/mild ventricular hypertrophy (non-remodeled, NR) and moderate/severe left ventricular hypertrophy (VH) according to guideline-recommended cut-offs for left ventricular (LV) wall thickness. The Kansas City Cardiomyopathy Questionnaire (KCCQ) was utilized to assess QoL; primary outcome was KCCQ change <5 from baseline to 30 days and 1 year.
RESULTS RESULTS
We analyzed 679 patients (NR: N = 389, VH: N = 290). Groups differed by septal thickness (1.12 cm vs. 1.44 cm, p < 0.001), posterior wall thickness (1.08 cm vs. 1.33 cm, p < 0.001), and LV internal diastolic diameter (4.34 cm vs. 4.19 cm, p = 0.006). The primary outcome was similar between NR and VH at 30 days (31.6 % vs. 28.6 %, p = 0.449) and 1 year (27.7 % vs. 21.5 %, p = 0.217). NR and VH experienced similar proportions of worsening, no change, or small, moderate, and large improvements in KCCQ score. Both groups experienced similar domain score changes and New York Heart Association class improvement. A subgroup analysis of VH patients did not reveal interaction with cavity size or stroke volume.
CONCLUSION CONCLUSIONS
Patients with significant ventricular remodeling by hypertrophy and aortic stenosis have similar QoL changes after intervention compared to patients without significant remodeling.

Identifiants

pubmed: 39433247
pii: S0914-5087(24)00207-7
doi: 10.1016/j.jjcc.2024.10.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Auteurs

Pavan Reddy (P)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Kalyan R Chitturi (KR)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Ilan Merdler (I)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Cheng Zhang (C)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Matteo Cellamare (M)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Itsik Ben-Dor (I)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Lowell F Satler (LF)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

Toby Rogers (T)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

William S Weintraub (WS)

MedStar Health Research Institute and Georgetown University, Washington, DC, USA.

Ron Waksman (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address: ron.waksman@medstar.net.

Classifications MeSH